Health Law & Business News

Gilead’s Covid-19 Drug May Get FDA Nod ‘Very Soon,’ Piper Says

March 18, 2020, 7:29 PM

Gilead’s treatment for the novel coronavirus “could be approved for Covid-19 very soon,” a Piper Sandler analyst said, after what he called “highly encouraging” data in 200 patients for a similar medicine developed by Fujifilm.

  • “We now believe the remdesivir clinical trial results are likely to be positive,” analyst Tyler Van Buren said of neutral-rated Gilead’s experimental medicine
    • “If successful, it could be approved for broad use in the coming months considering it’s safe, the bar for efficacy in the context of the ongoing global pandemic is low,” he said
  • NOTE: March 5, Gilead Analyst Sees Only 50% Chance That...

To read the full article log in. To learn more about a subscription click here.